Table 11Eating disorder—PCTs contributing to meta-analysis

Author, YearSubjectsNTreatmentsDurationOutcomes
Bissada et al. 2008180DSM-IV criteria for anorexia nervosa (restricting or binge / purge subtype) including a body index <= 17.5 kg/m234Placebo

Olanzapine 2.5-10 mg/day
10 weeksChange in BMI at 4 weeks:
Olanzapine vs. Placebo– WMD = 0.11 (-0.77, 0.99)

Change in BMI at 12 weeks:
Olanzapine vs. Placebo - WMD = 0.15 (-0.80, 1.10)
Brambilla et al. 2007182Anorexia nervosa per DSM-IV, restricted or binging-purging type30Placebo

Olanzapine 2.5-5 mg/day
12 weeksChange in BMI at 4 weeks:
Olanzapine vs. Placebo - WMD = -0.00 (-0.91, 0.91)

Change in BMI at 12 weeks:
Olanzapine vs. Placebo - WMD = 0.60 (-0.55, 1.75)
Brambilla et al. 2007183Anorexia nervosa according to DSM-IV20Placebo

Olanzapine 2.5-5 mg
12 weeksChange in BMI at 4 weeks:
Olanzapine vs. Placebo - WMD = -0.20 (-1.44, 1.04)

Change in BMI at 12 weeks:
Olanzapine vs. Placebo - WMD = 0.20 (-1.05, 1.45)
Court,2010185Anorexia nevosa per DSM-IV27Placebo

Quetiapine 100-400mg/day
12 weeksChange in BMI at 12 weeks: Quetiapine vs. Placebo - WMD = -0.10 (-1.74, 1.54)

BMI = body mass index; DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, 4th edition; WMD = weighted mean difference

From: Results

Cover of Off-Label Use of Atypical Antipsychotics: An Update
Off-Label Use of Atypical Antipsychotics: An Update [Internet].
Comparative Effectiveness Reviews, No. 43.
Maglione M, Maher AR, Hu J, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.